Questions? Chat with the founder on WhatsApp

Chat with the founder on WhatsApp
Arthneeti
HomeRankingsIPOScreenerInstitutions
HomeRankingsIPOScreenerInstitutions
Apollo Hospitals Enterprise LtdQ4 FY25Healthcare Services
Home/Stocks/Apollo Hospitals Enterprise Ltd/Q4 FY25

Apollo Hospitals Enterprise Ltd Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹8,780P/E: 59.4Market Cap: ₹1.2L CrSector: Healthcare Services

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 1 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

  • →Apollo Hospitals expects continued healthy volume growth driven by increased patient footfall across specialties.
  • →Revenue growth is anticipated to be robust, supported by higher patient admissions and expansion of specialty services.
  • →The management highlighted ongoing investments in digital initiatives and expansion of hospital network to drive future growth.
  • →There's a focus on improving operational efficiencies to support margin improvement alongside volume growth.
  • →International business and pharmacy segments are expected to contribute positively to revenue in coming quarters.
  • →Overall, the outlook remains positive with management confident of scaling up both revenues and volumes sustainably.

Margin guidance

The transcript indicates the following future growth expectations for Apollo Hospitals: - **Revenue Growth**: Expecting continued strong revenue growth driven by expansion in specialty and multi-specialty hospitals, and increased patient volumes. - **Operating Margins**: Anticipated improvement owing to scale benefits, operational efficiencies, and better cost management. - **Profitability**: Projected growth in operating profits supported by higher revenue and margin expansion. - **EPS Growth**: Earnings per share expected to grow in tandem with operating profits, driven by both volume growth and margin improvement. - **Strategic Initiatives**: Investment in digital health, telemedicine, and new hospital projects to further enhance growth. - **Cautious Optimism**: Management remains watchful of macroeconomic factors but confident about long-term sustainability. Overall, Apollo Hospitals expects healthy top-line and bottom-line expansion, with significant focus on operational leverage and margin enhancement.

3 more insights locked — sign up free to unlock

Fundraise plans

The transcript does not mention any current or future plans for fundraising through debt or equity.

Order book

The transcript does not provide specific figures or detailed commentary on the current or expected order book/pending orders for Apollo Hospitals. There is no mention of exact values or outlook related to order inflows or pending service agreements during the call. If you have any other specific sections or details you'd like to inquire about, please let me know!

Capex plans

Yes
The transcript does not explicitly mention current or future capex, capital investments, or strategic investments on page 2. There is no direct information regarding specific investments or capital expenditure plans provided in the content available. If you have access to other pages or sections, please share them for a more comprehensive review.

How does Apollo Hospitals Enterprise Ltd rank vs peers in Healthcare Services?

Pro feature
1Apollo Hospitals Enterprise Ltd
2Healthcare Services Company A
Rev 1Mar 2
3Healthcare Services Company B
Rev 2Mar 1
4Healthcare Services Company C
Rev 2Mar 3

See full Healthcare Services sector rankings

How does Apollo Hospitals Enterprise Ltd rank in Healthcare Services?

Compare Apollo Hospitals Enterprise Ltd against every Healthcare Services company (Q4 FY25) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Related research

Other quarters — Apollo Hospitals Enterprise Ltd

Q4 FY26Q3 FY26Q2 FY26Q1 FY26Q4 FY25Q3 FY25Q1 FY25Q4 FY24Q3 FY24Q2 FY24Q1 FY24Q4 FY23

Healthcare Services peers

Fortis Health. · Q1 FY27Syngene Intl. · Q4 FY26Dr Lal Pathlabs · Q1 FY27Narayana Hrudaya · Q1 FY27Health.Global · Q1 FY27
Apollo Hospitals Enterprise Ltd full stock analysisHealthcare Services sectorEarnings call directoryRankings dashboard

Questions about this analysis? Chat directly with the founder — real answers about the research, not a support bot.

WhatsApp the founder

Research team or advisory firm? Get earnings-call intelligence and ranking history as research inputs for your firm.

For Institutions

Arthneeti AI

AI-powered stock analysis from earnings call transcripts. Helping Indian investors make smarter decisions with data-driven insights.

Analysis

  • Stock Rankings
  • Sectors
  • Compare Stocks
  • IPO Dashboard
  • Stock Screener
  • Earnings Call Analysis
  • Stocks Under ₹500
  • Multibaggers

Tools

  • MF Overlap Checker
  • SIP Calculator
  • CAGR Calculator
  • FD vs Equity
  • All Calculators

Resources

  • Blog
  • Weekly Digest
  • Portfolio Analysis
  • Build Portfolio
  • Earnings Calendar
  • Q1 FY27 Earnings Hub

Company

  • Pricing
  • How Our Analysis Works
  • For Institutions
  • Terms of Service
  • Privacy Policy

Compare

  • vs Screener.in
  • vs Trendlyne
  • vs Tickertape
  • vs Moneycontrol Pro
+91 90841 32575 support@arthneeti.com Bengaluru, India

© 2026 Arthneeti AI. All rights reserved.

AI-analyzed data from 1,500+ company earnings calls

Continue your research

What Apollo Hospitals Enterprise Ltd's management said in earlier quarters

  • Q1 FY26 earnings call analysis →
  • Q2 FY26 earnings call analysis →
  • Q3 FY26 earnings call analysis →

Others in Healthcare Services this season

  • Rainbow Childrens Medicare Ltd (Q1 FY27)

    Volume growth supported by planned addition of 2,500 beds over 5 years (~15% CAGR) (Page 10). Key concall takeaways from Rainbow Childrens Medicare Ltd's Q1…

  • Dr Lal Pathlabs (Q1 FY27)

    140 crore to Rs. Key concall takeaways from Dr Lal Pathlabs's Q1 FY27 earnings call — and how it ranks against sector peers.

  • Vimta Labs Ltd (Q1 FY27)

    The company's various business units are growing at almost double the industry's CAGR (8%-11%). Key concall takeaways from Vimta Labs Ltd's Q1 FY27 earnings…

  • Dr Agarwal's Hea (Q1 FY27)

    Q1 FY27 revenue from operations grew 26% year-on-year to INR614 crores, driven by both volume and value growth (~16% each). Key concall takeaways from Dr…

Compare:vs Max Healthcarevs Fortis Health.vs Aster DM Quality